NewAmsterdam Pharma Announces Equity Inducement Grants in Accordance with Nasdaq Regulations
Oct 5, 2024
Biopharmaceutical Invest Advisor
Cingulate Inc. Shares Skyrocket on Key European Patent Approval
Aug 16, 2024
In-Depth Look at High-Profile Stocks: Alphabet, AbbVie, Qualcomm, and Flanigan's
Aug 15, 2024
Cellectar Biosciences Announces Q2 2024 Financial Results and Corporate Progress
Aug 14, 2024
Liquidia Corporation Announces Q2 2024 Financial Performance
Aug 8, 2024
NewAmsterdam Pharma Announces Equity Incentive Plan Grants Pursuant to Nasdaq Rule
Jul 4, 2024
Faruqi & Faruqi, LLP Investigates Investor Claims Against Altimmune, Inc. ALT
Jul 1, 2024
Sangamo Therapeutics Commences with a 'Sell' Rating from Investment Analysts
Jun 27, 2024
Anavex Life Sciences Announces Participation in H.C. Wainwright Neuro Conference
Jun 21, 2024
Anavex Life Sciences Expands Leadership Amidst Clinical Advancements
May 22, 2024
Cognition Therapeutics Announces Completion of Patient Enrollment for Phase 2 SHIMMER Study Evaluating CT1812 in Mild-to-Moderate Lewy Body Dementia
Apr 29, 2024
Ventyx Biosciences Shareholders Alert: Levi & Korsinsky LLP Announces Class Action Against Ventyx Biosciences, Inc. - VTYX
Mar 24, 2024
CytoMed Therapeutics Announces Complimentary Cell Banking for Select Shareholders
Mar 18, 2024
Cytokinetics Aligns with Global Partners to Mark International Rare Disease Day
Feb 29, 2024
Anavex Life Sciences to Showcase at the Prestigious 44th Annual TD Cowen Health Care Conference
Feb 26, 2024
Anavex Life Sciences Presents at the 44th Annual TD Cowen Health Care Conference
Feb 26, 2024
Rosen Law Firm Investigates Securities Claims Against Altimmune, Inc. - ALT
Feb 19, 2024
Cellectar Biosciences Announces Presentation at Oppenheimer Healthcare Conference; Investors Watch Closely
Feb 8, 2024
Immix Biopharma Sets Public Offering Price at $15 Million for Common Stock
Feb 7, 2024
Pliant Therapeutics Reports Promising Data from Bexotegrast Trial in Primary Sclerosing Cholangitis
Feb 5, 2024
Investor Alert: Key Stocks to Acquire Before 2023 Wraps Up
Dec 25, 2023
Connect Biopharma Set to Reveal Phase 2b Clinical Results for Asthma Treatment Rademikibart
Dec 12, 2023
Connect Biopharma Reveals Promising Phase 2b Results for Asthma Treatment
Dec 12, 2023
Connect Biopharma Set to Announce Pivotal Phase 2b Results for Asthma Drug Rademikibart
Dec 12, 2023
Adcentrx Ramps Up Series A+ Financing to $51 Million with New Investors Onboard
Dec 7, 2023
Connect Biopharma Reports Promising Long-Term Efficacy of Rademikibart in Key China Study for Atopic Dermatitis
Nov 21, 2023
Johnson & Johnson's Strategic Healthcare Investments Highlight Sector's Promising Stocks
Nov 16, 2023